The system
How the system worksThe DirectoryDispatchThe LedgerAI modelsAI agentsYour installationThe appThe research libraryWhat changes for your businessUse it from your softwareEverything it can do
Messaging
iMessageWhatsApp
Ads and leads
AdsCreativeLeads
Devices
Devices
Industries
RealtorsRestaurantsHome services
Explore
How it worksPermissions and limitsCompareSet upQuestionsText me

ss 31

Evidence is being populated by Grok web

Overview

Evidence is being populated by Grok web search.

References (4)
  1. Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential“Elamipretide (SS-31, MTP-131, Bendavia) is a mitochondria-targeting tetrapeptide designed to treat mitochondrial dysfunction via binding to cardiolipin.”
  2. SS-31: A promising therapeutic agent against bleomycin-induced pulmonary fibrosis“The mitochondria-targeting drug SS-31 exhibited potential in mitigating bleomycin-induced pulmonary fibrosis, improving mitochondrial function.”
  3. Elamipretide: The first cardiolipin-directed mitochondrial therapeutic for Barth syndrome approved under accelerated approval“On September 19, 2025, the U.S. Food and Drug Administration (FDA) granted accelerated approval to elamipretide, the first therapy directly targeting the mitochondrial etiology of BTHS.”
  4. Elamipretide (SS-31) Promotes Recovery by Preserving Mitochondrial Bioenergetics and Neural Remodeling after Spinal Cord Injury“Elamipretide (SS-31) is a mitochondria-targeting peptide with potential neuroprotective effects. Here, we investigated whether SS-31 improves functional outcomes after contusive SCI.”